ALXO Logo

ALX Oncology Holdings Inc. (ALXO) 

NASDAQ
Market Cap
$90.72M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
242 of 966
Rank in Industry
147 of 554

Largest Insider Buys in Sector

ALXO Stock Price History Chart

ALXO Stock Performance

About ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.

Insider Activity of ALX Oncology Holdings Inc.

Over the last 12 months, insiders at ALX Oncology Holdings Inc. have bought $198,514 and sold $2.12M worth of ALX Oncology Holdings Inc. stock.

On average, over the past 5 years, insiders at ALX Oncology Holdings Inc. have bought $52.18M and sold $11.34M worth of stock each year.

Highest buying activity among insiders over the last 12 months: GARCIA PETER S (Chief Financial Officer) — $307,015. Lettmann Jason (CHIEF EXECUTIVE OFFICER) — $49,771. Hemrajani Rekha (director) — $46,404.

The last purchase of 30,000 shares for transaction amount of $46,404 was made by Hemrajani Rekha (director) on 2024‑12‑02.

List of Insider Buy and Sell Transactions, ALX Oncology Holdings Inc.

2024-12-02Purchasedirector
30,000
0.0532%
$1.55$46,404-4.22%
2024-08-14SalePRESIDENT & CSO
1,937
0.0038%
$2.58$4,9970.00%
2024-08-14SaleCHIEF MEDICAL OFFICER
1,365
0.0027%
$2.58$3,5220.00%
2024-08-14SaleSVP, FINANCE AND CAO
564
0.0011%
$2.58$1,4550.00%
2024-07-11SalePRESIDENT & CSO
20,000
0.0516%
$7.90$158,0760.00%
2024-07-05SaleSVP, FINANCE AND CAO
1,823
0.0033%
$5.50$10,0250.00%
2024-07-01SalePRESIDENT & CSO
10,758
0.0204%
$5.82$62,5990.00%
2024-07-01SaleCHIEF MEDICAL OFFICER
3,273
0.0062%
$5.82$19,0450.00%
2024-07-01SaleSVP, FINANCE AND CAO
1,373
0.0026%
$5.82$7,9890.00%
2024-06-13PurchaseCHIEF FINANCIAL OFFICER
12,000
0.0229%
$8.53$102,338-75.59%
2024-06-04SalePRESIDENT & CSO
20,000
0.0387%
$8.43$168,652-74.43%
2024-05-13SaleCHIEF MEDICAL OFFICER
12,000
0.0243%
$15.94$191,339-85.29%
2024-05-06SalePRESIDENT & CSO
20,000
0.0399%
$15.92$318,334-85.20%
2024-04-16SalePRESIDENT & CSO
50,000
0.0977%
$14.20$710,195-82.26%
2024-04-04SalePRESIDENT & CSO
20,000
0.0396%
$11.15$223,036-76.16%
2024-03-14PurchaseCHIEF EXECUTIVE OFFICER
4,400
0.0085%
$11.31$49,771-45.56%
2024-01-04SaleSVP, Finance and CAO
2,717
0.0057%
$13.60$36,957-18.68%
2023-12-29SalePresident & CSO
7,179
0.0144%
$15.04$107,972-27.66%
2023-12-29SaleChief Medical Officer
3,128
0.0063%
$15.04$47,045-27.66%
2023-12-29SaleChief Financial Officer
1,893
0.0038%
$15.04$28,471-27.66%

Insider Historical Profitability

79.36%
Pons JaumePRESIDENT & CSO
591510
1.1215%
$1.72018
Randolph SophiaCHIEF MEDICAL OFFICER
325711
0.6175%
$1.72015
Lettmann JasonCHIEF EXECUTIVE OFFICER
171620
0.3254%
$1.7224+90.48%
GARCIA PETER SCHIEF FINANCIAL OFFICER
122348
0.232%
$1.7228+90.48%
Pinto ShellySVP, FINANCE AND CAO
91549
0.1736%
$1.7208
Hemrajani Rekhadirector
33000
0.0626%
$1.7220+90.48%
Adelman Robert J
5268325
9.9887%
$1.7210+90.48%
Graham G. Walmsleydirector
995000
1.8865%
$1.7220+34.88%
GOODMAN COREY S
850000
1.6116%
$1.7210+90.48%
Vivo Capital IX, LLC10 percent owner
789474
1.4968%
$1.7210+90.48%
LSV Associates, LLC10 percent owner
285956
0.5422%
$1.7214+90.48%
Pietzke SteffenVP Fin & Chief Acct Officer
3000
0.0057%
$1.7210+90.48%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
venBio$108.15M18.629.7M0%+$038.37
Fidelity Investments$83.88M14.447.52M+0.67%+$557,399.650.01
Redmile Group$48.24M8.34.33M+18.23%+$7.44M0.49
Vivo Capital$47.05M8.14.22M0%+$04.1
Cormorant Asset Management Lp$35.03M6.033.14M0%+$01.63
OrbiMed$30.31M5.222.72M-12.18%-$4.2M0.23
BlackRock$24.77M4.262.22M-0.6%-$150,881.80<0.01
The Vanguard Group$17.47M3.011.57M+4.26%+$714,213.19<0.0001
Bioimpact Capital Llc$14.14M2.441.27M+0.29%+$41,388.802.29
Citadel Advisors LLC$13.77M2.371.24M+0.17%+$23,504.200.01
Geode Capital Management$6.74M1.16604,714+3.36%+$219,460.15<0.01
State Street$6.18M1.06553,867+10.44%+$583,936.65<0.0001
Morgan Stanley$3.83M0.66343,137-17.07%-$787,814.29<0.0001
Northern Trust$2.73M0.47245,212+0.56%+$15,297.80<0.0001
Renaissance Technologies$2.61M0.45234,100-13.46%-$405,826.57<0.01
T. Rowe Price$2.6M0.45232,769-57.15%-$3.46M<0.0001
Charles Schwab$2.34M0.4209,759+0.77%+$17,784.25<0.01
Federated Hermes$2.25M0.39201,362+2.46%+$53,809.920.01
Adage Capital Partners Gp L L C$1.78M0.31160,0000%+$0<0.01
Goldman Sachs$1.75M0.3157,002+73.02%+$738,787.72<0.0001
Wellington Management Company$1.42M0.24127,037+57.44%+$516,791.51<0.0001
Marshall Wace$1.36M0.23121,546+950.62%+$1.23M<0.01
Squarepoint Ops LLC$1.19M0.2106,356New+$1.19M<0.01
Nuveen$1.18M0.2105,8940%+$0<0.0001
Los Angeles Capital Management LLC$1.1M0.1998,960-19.82%-$272,729.00<0.01
BNY Mellon$889,402.000.1579,767-7.58%-$72,909.85<0.0001
Standard Life$738,253.000.1366,2110%+$0<0.01
Two Sigma$729,823.000.1365,455-0.71%-$5,195.90<0.01
Millennium Management LLC$671,119.000.1260,190New+$671,119.00<0.0001
The Manufacturers Life Insurance Company$670,327.000.1260,119+25.09%+$134,469.03<0.01
Hrt Financial Llc$659,000.000.1159,186New+$659,000.00<0.01
Jane Street Capital$660,024.000.1159,195+35.77%+$173,906.48<0.01
State of Wisconsin Investment Board$606,181.000.154,366New+$606,181.00<0.01
Dimensional Fund Advisors$561,303.000.150,341-62.49%-$935,274.57<0.0001
RhumbLine Advisers$555,931.000.149,860+3.54%+$19,021.63<0.01
Td Asset Management Inc$546,350.000.0949,000-30.4%-$238,610.00<0.0001
Bank of America$525,779.000.0947,155-27.18%-$196,251.43<0.0001
Swiss National Bank$492,830.000.0944,200New+$492,830.00<0.0001
Citigroup$485,103.000.0843,507+817.29%+$432,218.55<0.0001
Nan Fung Group$467,743.000.0841,9500%+$00.51
JPMorgan Chase$467,152.000.0841,897-11.95%-$63,398.96<0.0001
DekaBank$468,000.000.0841,0000%+$0<0.01
AllianceBernstein$432,509.000.0738,790-3.72%-$16,725.02<0.0001
Walleye Capital$426,387.000.0738,241-50.87%-$441,417.20<0.01
Martingale Asset Management L P$403,575.000.0736,195-14.04%-$65,941.220.01
Cwm Advisors Llc$369,689.000.0633,156New+$369,689.000.04
Financial Advisory Group$350,300.000.0631,4170%+$00.06
American Century Investments$330,742.000.0629,663+39.95%+$94,406.92<0.0001
UBS$324,175.000.0629,074-6.18%-$21,341.09<0.0001
Connor Clark & Lunn Investment Management Ltd$324,287.000.0629,084+118.53%+$175,891.47<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.